Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $80.0 million.

  • Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) rose 11.58% to $80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.0 million, marking a year-over-year increase of 11.58%. This contributed to the annual value of $71.4 million for FY2024, which is 0.69% down from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Shares Outstanding (Diluted Average) stood at $80.0 million for Q3 2025, which was up 2.69% from $77.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Shares Outstanding (Diluted Average) high stood at $80.0 million for Q3 2025, and its period low was $68.3 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $71.6 million (2023), whereas its average is $72.9 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) fell by 0.88% in 2024, and later grew by 11.58% in 2025.
  • Quarterly analysis of 5 years shows Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) stood at $68.6 million in 2021, then increased by 2.69% to $70.4 million in 2022, then rose by 2.13% to $71.9 million in 2023, then decreased by 0.69% to $71.4 million in 2024, then grew by 11.58% to $80.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $80.0 million in Q3 2025, compared to $77.9 million in Q2 2025 and $76.1 million in Q1 2025.